Results 91 to 100 of about 18,247 (232)

An Engineered Glove for the Objective Assessment of Hand Dexterity in Patients With Systemic Sclerosis

ACR Open Rheumatology, Volume 8, Issue 7, July 2026.
Objective Hand disability is a major musculoskeletal functional impairment in systemic sclerosis (SSc), but its objective assessment remains challenging. The validated Hand Test System (HTS) engineered glove has provided quantitative dexterity data in rheumatic diseases.
Alberto Sulli, Elvis Hysa, Paolo Clini, Emanuele Gotelli, Tamara Vojinovic, Carmen Pizzorni, Ali Jaffal, Sabrina Paolino, Rosanna Campitiello, Vanessa Smith, Maurizio Cutolo   +10 more
wiley   +1 more source

Clinical and laboratory profile of juvenile-onset systemic sclerosis in a brazilian cohort

, 2020
To characterize the clinical and laboratory profile of juvenile-onset compared to adult-onset systemic sclerosis in a large Brazilian cohort. Methods: Retrospective analysis of a cohort of 1016 systemic sclerosis patients followed at the Scleroderma ...
Bortoluzzo, Adriana B., Luppino-Assad, Ana Paula, Andrade, Danieli C. O., Sampaio-Barros, Percival D., Marques-Neto, Joao Francisco, Del Rio, Ana Paula T.   +5 more
core   +1 more source

Periodontitis and Periodontal Conditions in Systemically Healthy Children and Adolescents

Journal of Clinical Periodontology, Volume 53, Issue 7, Page 1100-1198, July 2026.
ABSTRACT Objective To answer the PICoS question ‘in systemically healthy children and adolescents (Population), what are the main features of periodontitis, necrotising periodontal diseases (NPD) and other periodontal conditions (periodontal abscesses, endo‐periodontal lesions, traumatic occlusal forces, prosthesis‐ and tooth‐related factors ...
Inbar Eshkol‐Yogev, Nagore Ambrosio, Cheryl Somani, Elena Figuero, Lior Shapira, Janet Davies   +5 more
wiley   +1 more source

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.

, 1996
A worker in a polyvinyl chloride factory with rapidly progressive diffuse cutaneous scleroderma was treated with the humanized monoclonal antibody (Mab) CAMPATH-1H.
Chakravarty, K, Waldmann, H, Grant, JW, Hale, G, Waldmann, Herman, Hazleman, BL, Isaacs, JD   +6 more
core  

Seizures in a patient with diffuse scleroderma [PDF]

Postgraduate Medical Journal, 1995
A, Bhardwaj, P S, Badesha
openaire   +2 more sources

Lowered Angiogeneic Capability of Peripheral Blood Lymphocytes in Progressive Systemic Sclerosis (Scleroderma)

, 1984
Peripheral blood lymphocytes isolated from 19 patients with progressive systemic sclerosis (7 with diffuse scleroderma and 12 with CREST syndrome) and from 19 healthy control individuals were tested in a lymphocyte-induced angiogenesis assay.
Pawinska, Maria, Marek J. Kaminski, Maria Pawinska, Jablonska, Stefania, Slawomir Majewski, Kaminski, Marek J., Majewski, Slawomir, Stefania Jablonska   +7 more
core   +1 more source

Treatment of scleroderma by TCM

, 2010
Scleroderma is a rare persistent hardening and contraction of the body’s connective tissue, which often affect any organ, including the skin, heart, kidney, lung or oesophageal.
Yang Xiang (35912)
core   +1 more source

Nintedanib in systemic sclerosis treatment: a case report

Journal of Medical Case Reports
Background Nintedanib was approved for the treatment of scleroderma and scleroderma-related interstitial lung disease, as it decrease the forced expiratory volume. Case presentation A 48-year-old Asian female patient with systemic scleroderma 6 years ago
Maysoun Kudsi, Raghad Tarcha, Naram Khalayli   +2 more
doaj   +1 more source

Progressive systemic sclerosis (diffuse scleroderma) and radiotherapy

The British Journal of Radiology, 1990
The rheumatological manifestations of cancer are many and varied. Progressive systemic sclerosis has been reported both as an initial manifestation of malignancy (Caldwell & McCallum, 1986) and, of course, as coexisting with malignant disease. Surprisingly, only one case report is to be found in the literature reporting on the interaction between ...
S G, Cooper, J W, Denham
openaire   +2 more sources

Toward Personalized Medicine in Scleroderma: Classification of Scleroderma Patients into Stable “Inflammatory” and “Fibrotic” Subgroups

, 2012
There is no universally agreed-upon treatment for the fibrosis of scleroderma. Recently, much information has been generated relating to the fundamental mechanisms underlying this disease.
Leask, Andrew
core   +1 more source